No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Kaj Blennow?

Prof. Kaj Blennow

Direct Phone: +46 ** *** ** **       

Email: k***@***.se

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Company Description

The Sahlgrenska Academy is the faculty of health sciences at the University of Gothenburg. Education and research are conducted within the fields of pharmacy, medicine, odontology and health care sciences. About 4000 undergraduate students and 1000 postgr ... more

Find other employees at this company (381)

Background Information


Cerora Inc

Scientific Advisory Board Member
Alzheon Inc



Department of Clinical Neuroscience , Section of Experimental Neuroscience

The Sahlgrenska Academy at Goteborg University

doctorate in psychiatry

Göteborg University

medical degree

Lund University

Web References (95 Total References)

Scientific Advisory Board | Alzheon [cached]

Kaj Blennow, MD, PhD Professor of Clinical Neurochemistry, University of Gothenburg, Sweden Head of Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden

Resume: Blennow_K | Cerora [cached]

Kaj Blennow

Kaj Blennow, MD, PhD Medical Advisor
Kaj Blennow, MD, PhD is a professor at Sahlgrenska University Hospital in Goteborg, Sweden. Dr. Blennow conducts research on the mechanisms behind neurological disorders and over the past twenty (20) years, he has developed biochemical tests for Alzheimer's disease. He is a world-renowned researcher and clinician in both concussion and Alzheimer's disease.

Kaj Blennow, The ... [cached]

Kaj Blennow, The Sahlgrenska Academy at University of Gothenburg, Sweden

Kaj Blennow
Kaj Blennow

A recent review article in Alzheimer's ... [cached]

A recent review article in Alzheimer's and Dementia discusses the current state of cerebrospinal fluid-borne markers for Alzheimer disease.2 Tests that identify proteins in the CSF could be very specific to Alzheimer disease because the fluid directly interacts with brain tissue.3 According to first author, Kaj Blennow, MD, PhD, Professor of Clinical Neurochemistry at the Sahlgrenska University Hospital in Mölndal, Sweden, CSF is potentially better than blood since "a brain protein will be diluted in the larger blood volume, metabolized and degraded.

Blennow explains "They have been evaluated in hundreds of papers and very consistently show that more than 85%-90% of AD (and prodromal AD) cases have low Abeta42 and high total-tau and phospho-tau."
Levels of CSF amyloid-beta seem to decrease as post-mortem or biopsied brain levels increase, so it seems that the protein may deposit itself in the brain and while it correspondingly decreases in the fluid. CSF phosphorylated tau levels also correspond with the amount of neurofibrillary tangles found in a later autopsy. In addition, high levels of total tau in the CSF seem to indicate that mild cognitive impairment will quickly progress to full Alzheimer dementia. Unfortunately, the markers seem to be only good in the early stages of the disease. Blennow explains: "it seems that the AD biomarkers reach a plateau very early in disease progression, and thus do not change with progression."
Researchers may have another problem with developing a clinical test: the methods being used are not the same in every lab. The development of consistent assays is a high current priority in this field. According to Dr Blennow "what is needed is more work on standardization, both the analytical part and assay production, so that we can get uniform values between labs.

Professor Bengt Winblad at ... [cached]

Professor Bengt Winblad at Karolinska Institutet's Alzheimer's Disease Research Centre in Stockholm, Sweden; Niels Andreasen of Karolinska University Hospital, Lennart Minthon of the MAS University Hospital in Malmo and Kaj Blennow of the Sahlgrenska Academy in Gothenburg said the vaccine only affected harmful beta-amyloid linked to Alzheimer's disease.

Similar Profiles

Other People with this Name

Other people with the name Blennow

Kristina Blennow

Jörgen Blennow
Chalmers University of Technology

Kaj Blennow
Clinical Neurochemistry Lab

Andreas Blennow
Copenhagen Univ

Mats Blennow
Karolinska Institute

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory